Najla El Jurdi, MD
Hematology & Oncology · Minneapolis, MNNPI 1538424536
Payments from drug & device makers
What this record shows
This record is dominated by education: $88 of the $88 with a category attached, or 100.0%. E.r. Squibb & Sons, L.L.C. accounts for 84.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in MN, where the typical reported total is $238.
Across 3 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$74
- Acrotech Biopharma Inc.$14
Across 147 payments — averaging $5778.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$483K
- National Marrow Donor Program$233K
- Incyte Corporation$133K
What the payments were for
- Education$88100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $74 |
| Acrotech Biopharma Inc. | 1 | $14 |
How this compares
$88 in reported general payments places this provider in the 25th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 21 | $369,107 |
| Acyclovir | 27 | $647 |
| Rosuvastatin Calcium | 12 | $375 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $234 |
| Prednisone | 13 | $40 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Minneapolis
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Vicki MorrisonMinneapolis$354K
- Aimee MerinoMinneapolis$161K
- Daniel WeisdorfMinneapolis$64K
- Gautam JhaMinneapolis$55K
- Arpit RaoMinneapolis$46K
- Amit KulkarniMinneapolis$40K
- Gregory VercellottiMinneapolis$34K
- Veronika BachanovaMinneapolis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.